Singapore, May 28 -- The Experimental Drug Development Centre (EDDC), Singapore's national platform for drug discovery and development, has announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation for EBC-129 for the treatment of pancreatic ductal adenocarcinoma (PDAC).

EBC-129 is a first-in-class antibody drug conjugate (ADC) targeting a novel, tumour-specific N256 glycosylated epitope on CEACAM5 and CEACAM6. It is currently undergoing Phase 1 clinical trials for the treatment of patients with solid tumours with high unmet medical need.

The Fast Track Designation facilitates the expedited development of EBC-129, enabling more frequent engagement with the FDA to discuss the clinical development plan. I...